{"id":4140,"date":"2023-04-05T10:40:00","date_gmt":"2023-04-05T10:40:00","guid":{"rendered":"https:\/\/www.vistaar.ai\/?p=4140"},"modified":"2025-12-01T06:35:09","modified_gmt":"2025-12-01T06:35:09","slug":"pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1","status":"publish","type":"post","link":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/","title":{"rendered":"Pharma\/Biotech &#8211; USA, Europe Regulatory News, April 2023 Vol. 1"},"content":{"rendered":"\n<span class=\"wp-elements-de5c5712ebe1a35b13ff4243eed77e97\"  id=\"usa\"><\/span><br><br>\n<h3 class=\"wp-block-heading\" style=\"background:#e2e2e2;padding:12px;font-weight:bold;\">USA<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Releases Guidance on ISO Data Standards for Medicinal Products<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To advance alignment with global standards for medicinal product data exchange, the FDA has finalized guidance on implementing five ISO Identification of Medicinal Products (IDMP) standards.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>ICH Finalizes S12 Guideline on Gene Therapy Products<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The International Council for Harmonization (ICH) has completed a new guideline outlining nonclinical considerations for gene therapy development, paving the way for member nations to adopt their respective versions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Recommends RCTs for Oncology Drugs Seeking Accelerated Approval<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In new draft guidance, the FDA advises that sponsors pursuing Accelerated Approval (AA) for oncology drugs and biologics should generally rely on randomized controlled trials (RCTs) instead of single-arm studies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Guidance on Review Process for Pediatric Research Not Approvable by IRBs<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA has issued draft guidance describing how sponsors and IRBs should manage studies involving children when the research is not typically approvable. IRBs may refer such studies to FDA or HHS\u2019s OHRP. Given the sensitivity of pediatric research, higher scrutiny is required to ensure patient protection.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Final Guidance Defines \u2018Suspect\u2019 and \u2018Illegitimate\u2019 under DSCSA<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA released final guidance clarifying how it interprets the terms \u201csuspect\u201d and \u201cillegitimate\u201d as used in the Drug Supply Chain Security Act (DSCSA).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Shares Updated Thinking on Electronic Systems, Records, and Signatures<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">New draft guidance details the FDA\u2019s recommendations on implementing electronic systems, electronic signatures, and electronic records in clinical trials, including expectations for validation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDORA Enables Records-Based Inspections<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A provision in the Food and Drug Omnibus Reform Act of 2022 (FDORA) allows FDA to rely on manufacturer-submitted records and information in place of certain on-site inspections, signaling a potentially significant shift in inspection practices.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Guidance on Potency Assays for mAbs Targeting Viral Proteins<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA has released draft recommendations on developing potency assays throughout the lifecycle of monoclonal antibodies (mAbs) that directly target viral proteins.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Encourages RCTs for Accelerated Approval in Oncology<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA\u2019s latest draft guidance emphasizes RCTs as the preferred approach for oncology drugs seeking accelerated approval. Sponsors may use a single RCT to both support accelerated approval and confirm clinical benefit, or run separate trials for early and long-term endpoints.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Outlines Strategy for Digital Health Technologies in Trials<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA plans public meetings and new guidances on digital health technologies (DHTs) used in drug clinical trials, addressing concerns about the accuracy and reliability of DHTs for data collection.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Draft Guidance on Pharmacogenomic Data Submissions<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA has issued draft guidance clarifying what pharmacogenomic findings should be included in INDs, NDAs, and BLAs. It also outlines recommended formats and detail levels. Once finalized, it will replace 2005 guidance.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Industry Seeks More Clarity on Dosage and Administration Labeling<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Despite expanded guidance on dosage and administration labeling, industry representatives are requesting more specific direction on handling unique or complex cases. The draft aims to improve consistency in critical prescribing information such as dose ranges, titration, and duration.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Issues Guidance on Long-Acting Local Anesthetics<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In line with efforts to reduce opioid use, the FDA has published draft guidance for developing long-acting local anesthetics designed to deliver pain relief for days instead of hours.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>FDA Offers Recommendations for Macular Degeneration Drug Trials<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA\u2019s 8-page draft guidance provides recommendations on eligibility criteria, endpoints, and trial design for macular degeneration products. Sponsors may consider superiority or noninferiority designs using approved comparators.<\/p>\n\n\n\n<span  id=\"europe\"><\/span><br><br>\n<h3 style=\"background:#e2e2e2;padding:12px;font-weight:bold;\">EUROPE<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>EMA Highlights Innovations in Trials and Real-World Data<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In its mid-term assessment of the \u201cRegulatory Science Strategy to 2025,\u201d the EMA notes significant progress, including the launch of the EU Clinical Trials Information System and efforts to strengthen the EU\u2019s position in innovative research.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Updated Rules for EMA Fees under Council Regulation (EC) No 297\/95<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Effective 1 April 2023, the EMA has revised implementing rules for marketing authorization fees, variation fees, annual fees, and inspection fees.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Guideline on Computerized Systems and Electronic Data in Clinical Trials<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The EMA has released final guidance on electronic data capture in clinical trials, replacing the earlier reflection paper from 2010 and describing expectations for electronic source data.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Explanatory Note on EMA Fee Structure<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The latest explanatory note outlines revisions reflecting a 10.4% inflation adjustment, with rounding changes applied to administrative and non\u2011administrative fees.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>EMA Q&amp;A on Raw Data Pilot for MAAs<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The EMA issued a Q&amp;A document to address common sponsor questions related to the raw clinical data review pilot for marketing authorization applications and post-authorization submissions. The pilot aims to evaluate scientific, operational, and technological value of raw data access.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Regulatory and Industry Perspectives on EU GMP Annex 1 Implementation<\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color wp-elements-71537214d8ba6565fc51542a811aeaa8 wp-block-paragraph\">As the revised Annex 1 for sterile product manufacturing takes effect, EU regulators expect firms to adopt robust contamination control strategies and implement PUPSIT filter testing. FDA inspectors, while not enforcing Annex 1, are aligning their inspection focus with related quality expectations.<\/p>\n\n\n<div style=\"color:#00bab9;font-size:16px\" class=\"taxonomy-post_tag has-link-color wp-elements-2fb81544d083efd7ff848ed24a17d721 wp-block-post-terms has-text-color\"><span class=\"wp-block-post-terms__prefix\"><strong><mark style=\"background-color:#ffffff\" class=\"has-inline-color has-black-color\">Tags<\/mark>:<\/strong> <\/span><a href=\"https:\/\/stage-websites.ddismart.com\/vistaar\/tag\/biotech-regulatory-news\/\" rel=\"tag\">Biotech Regulatory News<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"https:\/\/stage-websites.ddismart.com\/vistaar\/tag\/eu-regulatory-news\/\" rel=\"tag\">EU Regulatory News<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"https:\/\/stage-websites.ddismart.com\/vistaar\/tag\/european-medicines-agency\/\" rel=\"tag\">European Medicines Agency<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"https:\/\/stage-websites.ddismart.com\/vistaar\/tag\/pharma-regulatory-news\/\" rel=\"tag\">Pharma Regulatory News<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"https:\/\/stage-websites.ddismart.com\/vistaar\/tag\/regulatory-news\/\" rel=\"tag\">Regulatory News<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"https:\/\/stage-websites.ddismart.com\/vistaar\/tag\/us-fda\/\" rel=\"tag\">US FDA<\/a><span class=\"wp-block-post-terms__separator\">, <\/span><a href=\"https:\/\/stage-websites.ddismart.com\/vistaar\/tag\/usa-regulatory-news\/\" rel=\"tag\">USA Regulatory News<\/a><\/div>\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>USA FDA Releases Guidance on ISO Data Standards for Medicinal Products To advance alignment with global standards for medicinal product data exchange, the FDA has finalized guidance on implementing five ISO Identification of Medicinal Products (IDMP) standards. ICH Finalizes S12 Guideline on Gene Therapy Products The International Council for Harmonization (ICH) has completed a new [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1951,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[639],"tags":[122,121,238,123,112,237,124],"class_list":["post-4140","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","tag-biotech-regulatory-news","tag-eu-regulatory-news","tag-european-medicines-agency","tag-pharma-regulatory-news","tag-regulatory-news","tag-us-fda","tag-usa-regulatory-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1<\/title>\r\n<meta name=\"description\" content=\"Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1\" \/>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/\" \/>\r\n<meta property=\"og:locale\" content=\"en_US\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1\" \/>\r\n<meta property=\"og:description\" content=\"Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/\" \/>\r\n<meta property=\"og:site_name\" content=\"Vistaar\" \/>\r\n<meta property=\"article:published_time\" content=\"2023-04-05T10:40:00+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2025-12-01T06:35:09+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-content\/uploads\/2024\/01\/Biopharma-min.jpg\" \/>\r\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\r\n\t<meta property=\"og:image:height\" content=\"555\" \/>\r\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\r\n<meta name=\"author\" content=\"admin\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/#\\\/schema\\\/person\\\/d62b304dd6b8cc3c3b5f77783874af43\"},\"headline\":\"Pharma\\\/Biotech &#8211; USA, Europe Regulatory News, April 2023 Vol. 1\",\"datePublished\":\"2023-04-05T10:40:00+00:00\",\"dateModified\":\"2025-12-01T06:35:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/\"},\"wordCount\":804,\"image\":{\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Biopharma-min.jpg\",\"keywords\":[\"Biotech Regulatory News\",\"EU Regulatory News\",\"European Medicines Agency\",\"Pharma Regulatory News\",\"Regulatory News\",\"US FDA\",\"USA Regulatory News\"],\"articleSection\":[\"Biopharma\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/\",\"url\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/\",\"name\":\"Pharma\\\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Biopharma-min.jpg\",\"datePublished\":\"2023-04-05T10:40:00+00:00\",\"dateModified\":\"2025-12-01T06:35:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/#\\\/schema\\\/person\\\/d62b304dd6b8cc3c3b5f77783874af43\"},\"description\":\"Pharma\\\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Biopharma-min.jpg\",\"contentUrl\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Biopharma-min.jpg\",\"width\":1200,\"height\":555,\"caption\":\"Biopharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/blog\\\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma\\\/Biotech &#8211; USA, Europe Regulatory News, April 2023 Vol. 1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/#website\",\"url\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/\",\"name\":\"Vistaar\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/#\\\/schema\\\/person\\\/d62b304dd6b8cc3c3b5f77783874af43\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0d089543c02b6aad11bd03612ee5efc6ddd700450a82976e93b20516f42f6cf4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0d089543c02b6aad11bd03612ee5efc6ddd700450a82976e93b20516f42f6cf4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0d089543c02b6aad11bd03612ee5efc6ddd700450a82976e93b20516f42f6cf4?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.vistaar.ai\"],\"url\":\"https:\\\/\\\/stage-websites.ddismart.com\\\/vistaar\\\/author\\\/admin\\\/\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1","description":"Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/","og_locale":"en_US","og_type":"article","og_title":"Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1","og_description":"Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1","og_url":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/","og_site_name":"Vistaar","article_published_time":"2023-04-05T10:40:00+00:00","article_modified_time":"2025-12-01T06:35:09+00:00","og_image":[{"width":1200,"height":555,"url":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-content\/uploads\/2024\/01\/Biopharma-min.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":false,"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/#article","isPartOf":{"@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/"},"author":{"name":"admin","@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/#\/schema\/person\/d62b304dd6b8cc3c3b5f77783874af43"},"headline":"Pharma\/Biotech &#8211; USA, Europe Regulatory News, April 2023 Vol. 1","datePublished":"2023-04-05T10:40:00+00:00","dateModified":"2025-12-01T06:35:09+00:00","mainEntityOfPage":{"@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/"},"wordCount":804,"image":{"@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/#primaryimage"},"thumbnailUrl":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-content\/uploads\/2024\/01\/Biopharma-min.jpg","keywords":["Biotech Regulatory News","EU Regulatory News","European Medicines Agency","Pharma Regulatory News","Regulatory News","US FDA","USA Regulatory News"],"articleSection":["Biopharma"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/","url":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/","name":"Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1","isPartOf":{"@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/#primaryimage"},"image":{"@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/#primaryimage"},"thumbnailUrl":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-content\/uploads\/2024\/01\/Biopharma-min.jpg","datePublished":"2023-04-05T10:40:00+00:00","dateModified":"2025-12-01T06:35:09+00:00","author":{"@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/#\/schema\/person\/d62b304dd6b8cc3c3b5f77783874af43"},"description":"Pharma\/BioTech - USA, Europe Regulatory News, April 2023 Vol. 1","breadcrumb":{"@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/#primaryimage","url":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-content\/uploads\/2024\/01\/Biopharma-min.jpg","contentUrl":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-content\/uploads\/2024\/01\/Biopharma-min.jpg","width":1200,"height":555,"caption":"Biopharma"},{"@type":"BreadcrumbList","@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/blog\/pharma-biotech-usa-europe-regulatory-news-april-2023-vol-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stage-websites.ddismart.com\/vistaar\/"},{"@type":"ListItem","position":2,"name":"Pharma\/Biotech &#8211; USA, Europe Regulatory News, April 2023 Vol. 1"}]},{"@type":"WebSite","@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/#website","url":"https:\/\/stage-websites.ddismart.com\/vistaar\/","name":"Vistaar","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stage-websites.ddismart.com\/vistaar\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/stage-websites.ddismart.com\/vistaar\/#\/schema\/person\/d62b304dd6b8cc3c3b5f77783874af43","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/0d089543c02b6aad11bd03612ee5efc6ddd700450a82976e93b20516f42f6cf4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0d089543c02b6aad11bd03612ee5efc6ddd700450a82976e93b20516f42f6cf4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0d089543c02b6aad11bd03612ee5efc6ddd700450a82976e93b20516f42f6cf4?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.vistaar.ai"],"url":"https:\/\/stage-websites.ddismart.com\/vistaar\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/posts\/4140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/comments?post=4140"}],"version-history":[{"count":5,"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/posts\/4140\/revisions"}],"predecessor-version":[{"id":6815,"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/posts\/4140\/revisions\/6815"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/media\/1951"}],"wp:attachment":[{"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/media?parent=4140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/categories?post=4140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stage-websites.ddismart.com\/vistaar\/wp-json\/wp\/v2\/tags?post=4140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}